Opthea Limited (OPT) reported positive data from the Phase 1b dose escalation study of its OPT-302 for patients with diabetic macular edema (DME). Eyes with persistent DME sub-responsive to multiple prior anti-VEGF-A injections demonstrated visual and anatomic improvement at 12 weeks following conversion to OPT-302 combination treatment. A dose-response relationship of increased gains in visual acuity (VA) was shown with ascending dose levels of OPT-302 combination treatment which also produced reductions in retinal swelling.
http://crweworld.com/article/news-p...n-study-for-opt-302-in-diabetic-macular-edema
Opthea Limited (OPT) reported positive data from the Phase 1b...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
-0.045(6.43%) |
Mkt cap ! $855.6M | |||
| Open | High | Low | Value | Volume |
| 69.5¢ | 69.5¢ | 63.0¢ | $2.808M | 4.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49996 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 50869 | 6 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |
